Michael Schlichting

8.4k total citations · 4 hit papers
43 papers, 6.2k citations indexed

About

Michael Schlichting is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, Michael Schlichting has authored 43 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 9 papers in Pathology and Forensic Medicine and 9 papers in Cancer Research. Recurrent topics in Michael Schlichting's work include Colorectal Cancer Treatments and Studies (14 papers), Cancer Genomics and Diagnostics (9 papers) and Genetic factors in colorectal cancer (7 papers). Michael Schlichting is often cited by papers focused on Colorectal Cancer Treatments and Studies (14 papers), Cancer Genomics and Diagnostics (9 papers) and Genetic factors in colorectal cancer (7 papers). Michael Schlichting collaborates with scholars based in Germany, United States and United Kingdom. Michael Schlichting's co-authors include Eric Van Cutsem, Philippe Rougier, Gunnar Folprecht, Claus-Henning Köhne, Ilhan Celik, Sabine Tejpar, Tamás Pintér, Paul Ruff, Erika Hitre and Robert Lim and has published in prestigious journals such as New England Journal of Medicine, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Michael Schlichting

41 papers receiving 6.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

2009 2.9k citations Eric Van Cutsem, Claus-Henning Köhne et al. New England Journal of Medicine profile →
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

2011 1.4k citations Eric Van Cutsem, Claus-Henning Köhne et al. Journal of Clinical Oncology profile →
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

2017 466 citations Michael Schlichting et al. Journal of Clinical Oncology profile →
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials

2012 447 citations Carsten Bokemeyer, Eric Van Cutsem et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Michael Schlichting	5.2k	2.0k	1.6k	1.4k	1.2k	43	6.2k
Claus-Henning Köhne	4.7k 0.9×	1.9k 0.9×	1.5k 0.9×	1.5k 1.1×	929 0.8×	13	5.5k
Kelly S. Oliner	4.6k 0.9×	2.6k 1.3×	1.6k 1.0×	1.3k 1.0×	1.0k 0.8×	68	6.4k
Chiara Cremolini	6.1k 1.2×	2.3k 1.1×	2.1k 1.3×	1.7k 1.2×	1.0k 0.9×	335	7.6k
Angela Zubel	4.8k 0.9×	2.0k 1.0×	1.4k 0.9×	1.2k 0.9×	744 0.6×	34	5.8k
Christiane Langer	4.6k 0.9×	2.0k 1.0×	1.5k 1.0×	962 0.7×	743 0.6×	26	5.8k
Gianluca Masi	6.2k 1.2×	2.5k 1.2×	1.7k 1.0×	2.5k 1.8×	1.5k 1.3×	257	7.6k
Anatoly Makhson	4.2k 0.8×	1.9k 0.9×	1.1k 0.7×	1.2k 0.8×	758 0.6×	11	5.3k
Rafael G. Amado	5.0k 1.0×	2.3k 1.1×	1.5k 1.0×	1.4k 1.0×	753 0.6×	57	6.7k
Dominik Paul Modest	3.5k 0.7×	1.6k 0.8×	1.1k 0.7×	900 0.6×	833 0.7×	206	4.4k
Sabine Tejpar	4.1k 0.8×	1.9k 1.0×	1.7k 1.0×	929 0.7×	700 0.6×	78	5.3k

Countries citing papers authored by Michael Schlichting

Since Specialization

Citations

This map shows the geographic impact of Michael Schlichting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Schlichting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Schlichting more than expected).

Fields of papers citing papers by Michael Schlichting

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Schlichting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Schlichting. The network helps show where Michael Schlichting may publish in the future.

Co-authorship network of co-authors of Michael Schlichting

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Schlichting. A scholar is included among the top collaborators of Michael Schlichting based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Schlichting. Michael Schlichting is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jun, Yesl, R. Hugh F. Bender, Weijuan Gong, et al.. (2025). Engineered vasculature induces functional maturation of pluripotent stem cell-derived islet organoids. Developmental Cell. 60(18). 2455–2469.e7. 4 indexed citations

Zhang, Xinke, et al.. (2023). Development of a Conceptual Model of the Patient Experience in Small Cell Lung Cancer: A Qualitative Interview Study. Oncology and Therapy. 11(2). 231–244. 4 indexed citations

Schlichting, Michael, Michael Hennig, K. Rüdell, et al.. (2022). Is IQWiG's 15% Threshold Universally Applicable in Assessing the Clinical Relevance of Patient-Reported Outcomes Changes? An ISPOR Special Interest Group Report. Value in Health. 25(9). 1463–1468. 8 indexed citations

Latimer, Nicholas, et al.. (2022). Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?. Value in Health. 26(2). 234–242. 2 indexed citations

Chiou, Joshua, Chun Zeng, Cheng Zhang, et al.. (2021). Single-cell chromatin accessibility identifies pancreatic islet cell type– and state-specific regulatory programs of diabetes risk. Nature Genetics. 53(4). 455–466. 89 indexed citations

Kapetanakis, Venediktos, Michael Schlichting, K. Jack Ishak, et al.. (2021). How Assessment-Schedule Matching Limits Bias When Comparing Progression-Free Survival in Single-Arm Studies: An Application in Second-Line Urothelial Carcinoma Treatments. Value in Health. 24(8). 1137–1144. 2 indexed citations

Hatswell, Anthony J., Ash Bullement, Michael Schlichting, & Murtuza Bharmal. (2020). What is the Impact of the Analysis Method Used for Health State Utility Values on QALYs in Oncology? A Simulation Study Comparing Progression-Based and Time-to-Death Approaches. Applied Health Economics and Health Policy. 19(3). 389–401. 6 indexed citations

Grote, H., Zheng Feng, Michael Schlichting, et al.. (2020). Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay. Journal of Thoracic Oncology. 15(8). 1306–1316. 25 indexed citations

Bharmal, Murtuza, et al.. (2020). Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with metastatic Merkel cell carcinoma. Health and Quality of Life Outcomes. 18(1). 145–145. 6 indexed citations

10.

Bullement, Ash, et al.. (2020). Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. BMC Medical Research Methodology. 20(1). 103–103. 13 indexed citations

11.

Bharmal, Murtuza, Matthias Hünger, & Michael Schlichting. (2019). Psychometric Properties of EQ-5D-5L Scoring Algorithms for the United Kingdom in Metastatic Merkel Cell Carcinoma. Value in Health. 22(10). 1170–1177. 2 indexed citations

12.

D’Angelo, Sandra P., Matthias Hünger, Andrew S. Brohl, et al.. (2019). Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. Cancer Immunology Immunotherapy. 68(4). 609–618. 17 indexed citations

13.

Kapetanakis, Venediktos, Michael Schlichting, K. Jack Ishak, et al.. (2019). Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies. PharmacoEconomics. 37(12). 1537–1551. 15 indexed citations

14.

Bharmal, Murtuza, et al.. (2017). Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma. Health and Quality of Life Outcomes. 15(1). 247–247. 13 indexed citations

15.

Cutsem, Eric Van, Robert J. Fram, Michael Schlichting, & David P. Ryan. (2013). Phase 3 Trial of Gemcitabine and Th-302 Compared with Gemcitabine and Placebo in Patients with Pancreatic Adenocarcinoma: the Maestro Trial. Annals of Oncology. 24. iv85–iv85. 2 indexed citations

16.

Douillard, Jean‐Yves, George Fountzilas, Carlo Barone, et al.. (2013). FOLFOX4 With Cetuximab vs. UFOX With Cetuximab as First-Line Therapy in Metastatic Colorectal Cancer: The Randomized Phase II FUTURE Study. Clinical Colorectal Cancer. 13(1). 14–26.e1. 21 indexed citations

17.

Cutsem, Eric Van, Sabine Tejpar, Dirk Vanbeckevoort, et al.. (2012). Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study. Journal of Clinical Oncology. 30(23). 2861–2868. 94 indexed citations

18.

Cutsem, Eric Van, Claus-Henning Köhne, István Láng, et al.. (2011). Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. Journal of Clinical Oncology. 29(15). 2011–2019. 1441 indexed citations breakdown →

19.

Tejpar, Sabine, Carsten Bokemeyer, Ilhan Celik, et al.. (2011). Kras mutations and outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. Annals of Oncology. 22. 3 indexed citations

20.

Cutsem, Eric Van, Claus-Henning Köhne, Erika Hitre, et al.. (2009). Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. New England Journal of Medicine. 360(14). 1408–1417. 2902 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact